Completed PHASE1 INTERVENTIONAL 3-arm NCT00513110

A Possible Therapeutic Role for Adenosine During Inflammation

Sponsor: Radboud University Medical Center

Interventions AMPD1 polymorphism Caffeine infusion placebo

Updated 7 times since 2017 Last updated: Sep 30, 2009 Started: Aug 31, 2007 Primary completion: Aug 31, 2008 Completion: Aug 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00513110, this PHASE1 trial focuses on Endotoxemia and remains completed. Sponsored by Radboud University Medical Center, it has been updated 7 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Mar 2022 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Mar 2022 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Aug 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Radboud University Medical Center

Data source: Radboud University Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nijmegen, Netherlands